GEO reported Q1 2025 net income of $19.6 million ($0.14 per diluted share) on revenues of $605 million, with adjusted EBITDA of $100 million; full-year 2025 guidance is $0.77–$0.89 per share on $2.53 billion revenue and $465–$490 million adjusted EBITDA.
The company is positioning for significant growth in the second half of 2025, driven by new ICE contracts (Delaney Hall and Northlake facilities) expected to add over $130 million in annualized revenue and 2,800 beds, with further upside from additional idle facility activations.
GEO is investing $70 million to expand ICE service capabilities and expects total 2025 capital expenditures of $120–$135 million; net debt reduction of $150–$175 million is targeted, with potential acceleration from a $312 million Oklahoma facility sale.
Utilization at ICE-contracted facilities reached 16,000 beds (highest in 5+ years), with ongoing discussions for additional contracts that could bring total annualized revenue potential from idle/underutilized beds to $500–$600 million at 25–30% margins.
The company anticipates a "tale of two halves" in 2025: higher expenses and capex in H1 to prepare for growth, with revenue and profitability ramping in H2 as new contracts activate; share repurchases and capital returns are under consideration for late 2025 or 2026 as leverage targets are met and major contract extensions (e.g., ISAP) are secured.